Sarcoma News

Ripretinib did not extend PFS compared with sunitinib for patients with advanced gastrointestinal stromal tumor who previously received imatinib, according to randomized phase 3 study results presented during the ASCO Plenary Series.

The FDA granted rare pediatric disease designation to IMX-110 for treatment of children with rhabdomyosarcoma.

The FDA approved sirolimus protein-bound particles for injectable suspension (albumin-bound) for treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor.

Half of patients with relapsed or refractory solid tumors achieved objective response to an infusion of IMA203, according to study results presented at Society for the Immunotherapy of Cancer Annual Meeting.

Ripretinib failed to prolong PFS compared with sunitinib among patients with gastrointestinal stromal tumor who received prior treatment with imatinib, according to results of the phase 3 INTRIGUE study released by the agent’s manufacturer.

Evaluation of multiple classifiers, both alone and in combination, supports the decision to focus on cell-free DNA methylation patterns to detect cancer and predict the cancer signal origin, according to a presentation at ESMO Congress 2021.

To advance health equity, it is time to normalize the collection of sexual orientation and gender identity (SOGI) data in clinical practice and in health services research.

Standard cancer care may fail to adequately address the needs of LGBTQ+ individuals, who face substantial disparities in access to screening, treatment and outcomes.

More than a third of patients with solid tumors showed evidence of antitumor response after treatment with ADP-A2M4CD8, according to data presented at the virtual ESMO Congress.

Few scientific advances have generated the optimism and enthusiasm that surround CRISPR.